Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 10264.026 | uM | inf | inf | 0.9706 | 0.9706 | 0.0000 | -0.0006 | 0.1039 | 1.5047 | |
| LY2 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9536.006 | uM | inf | inf | 0.9716 | 0.9716 | 0.0000 | 0.0671 | 0.1220 | 1.2564 | |
| 600MPE | HR+ | Luminal | Dichloroacetate | PDK | PDK | 13091.176 | uM | inf | inf | 0.9717 | 0.9717 | 0.0000 | 0.0439 | -0.10 | 0.8746 | |
| BT-20 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 10581.142 | uM | inf | inf | 0.9722 | 0.9722 | 0.0000 | 0.0008 | -0.0078 | 0.7885 | |
| HCC2185 | TNBC | Luminal | FR180204 | ERK1/2 | MAPK | 10996.149 | uM | inf | inf | 0.9724 | 0.9724 | 0.0000 | 0.0208 | 0.0401 | 0.4765 | |
| LY2 | HR+ | Luminal | Ribavirin | 15391.211 | uM | inf | inf | 0.9725 | 0.9725 | 0.0000 | 0.0076 | -0.0134 | 1.2835 | |||
| MDA-MB-361 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 10999.155 | uM | inf | inf | 0.9727 | 0.9727 | 0.0000 | -0.0387 | -1.6882 | 0.7370 | |
| HCC38 | TNBC | Basal B | AG1024 | IGF1R | RTK | 7469.066 | uM | inf | inf | 0.9727 | 0.9727 | 0.0000 | 0.0128 | -0.0529 | 2.0057 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 12003.145 | uM | inf | inf | 0.9728 | 0.9728 | 0.0000 | 0.0104 | 0.0000 | 0.9611 | |
| HCC2185 | TNBC | Luminal | Selumetinib | MEK | MAPK | 10996.155 | uM | inf | inf | 0.9728 | 0.9728 | 0.0000 | 0.0875 | 0.0658 | 0.6934 | |
| SK-BR-3 | HER2amp | Luminal | Trametinib | MEK | MAPK | 9759.012 | uM | inf | inf | 0.9728 | 0.9728 | 0.0000 | -0.0132 | -0.0794 | 1.3591 | |
| 600MPE | HR+ | Luminal | Glycyl-H-1152 | ROCK2 | 12224.16 | uM | inf | inf | 0.9729 | 0.9729 | 0.0000 | 0.0688 | 0.1842 | 0.7734 | ||
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9453.125 | uM | inf | inf | 0.9729 | 0.9729 | 0.0000 | 0.0022 | 0.4453 | 1.2351 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7896.042 | uM | inf | inf | 0.9737 | 0.9737 | 0.0000 | -0.0276 | -0.7203 | 1.1632 | |
| MDA-MB-415 | HR+ | Luminal | AG1024 | IGF1R | RTK | 7512.066 | uM | inf | inf | 0.9738 | 0.9738 | 0.0000 | -0.0064 | -0.0661 | 0.8629 | |
| SUM1315MO2 | TNBC | Basal B | Ribavirin | 15401.211 | uM | inf | inf | 0.9740 | 0.9740 | 0.0000 | 0.0925 | 0.0630 | 0.4079 | |||
| HCC1395 | TNBC | Basal B | Purvalanol A | CDK1 | CDK | 7436.067 | uM | inf | inf | 0.9747 | 0.9747 | 0.0000 | 0.0019 | 0.2592 | 1.2834 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7895.018 | uM | inf | inf | 0.9756 | 0.9756 | 0.0000 | 0.0240 | -0.0375 | 1.2916 | |
| SUM229PE | TNBC | - | Ribavirin | 15359.211 | uM | inf | inf | 0.9761 | 0.9761 | 0.0000 | -0.0092 | -0.0004 | 1.4356 | |||
| HCC1428 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7441.102 | uM | inf | inf | 0.9761 | 0.9761 | 0.0000 | 0.0202 | 0.1949 | 0.9144 | |
| Hs 578T | TNBC | Basal B | Nutlin 3a | MDM2 | MDM2 | 7475.066 | uM | inf | inf | 0.9761 | 0.9761 | 0.0000 | -0.0283 | -0.7384 | 2.7689 | |
| 184A1 | NM | Basal | GM6001 | MMP | MMP | 5895.096 | uM | inf | inf | 0.9763 | 0.9763 | 0.0000 | -0.0141 | -0.1057 | 1.4232 | |
| Hs 578T | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 10694.154 | uM | inf | inf | 0.9764 | 0.9764 | 0.0000 | -0.0084 | -0.0364 | 2.3045 | |
| SUM159PT | TNBC | Basal B | Sulindac sulfide | COX1/2 | COX | 10520.136 | uM | inf | inf | 0.9767 | 0.9767 | 0.0000 | -0.0015 | 0.0597 | 4.0331 | |
| MDA-MB-415 | HR+ | Luminal | PS-1145 | IKK | NFKB | 7511.065 | uM | inf | inf | 0.9780 | 0.9780 | 0.0000 | 0.0568 | 0.1924 | 1.2217 |